Updates are available Correction dated 2024-04-25
Click to view Correction: https://doi.org/10.1038/s41588-024-01765-z
-
Authors
Natri, Heini M. http://orcid.org/0000-0003-4698-6103
Del Azodi, Christina B.
Peter, Lance
Taylor, Chase J. http://orcid.org/0000-0002-7942-0483
Chugh, Sagrika
Kendle, Robert
Chung, Mei-i
Flaherty, David K.
Matlock, Brittany K.
Calvi, Carla L.
Blackwell, Timothy S.
Ware, Lorraine B. http://orcid.org/0000-0002-9429-4702
Bacchetta, Matthew http://orcid.org/0000-0003-4456-4484
Walia, Rajat http://orcid.org/0000-0001-5036-2921
Shaver, Ciara M.
Kropski, Jonathan A. http://orcid.org/0000-0002-8923-1344
McCarthy, Davis J. http://orcid.org/0000-0002-2218-6833
Banovich, Nicholas E. http://orcid.org/0000-0003-2604-3247
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R01HG011886, R01HG011886)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL145372, P30 CA068485, P01HL092870, R01HL126176, R01HL158906, K08HL136888, R01HL145372)
Doris Duke Charitable Foundation
U.S. Department of Defense (W81XWH1910416)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R01HG011886)
Department of Health | National Health and Medical Research Council (GNT1195595, GNT1162829)
- License Information
-
More Information
Article History
Received: 21 March 2023
Accepted: 28 February 2024
First Online: 28 March 2024
Change Date: 25 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41588-024-01765-z
Competing interests
: J.A.K. reports advisory board fees from Boehringer Ingelheim, nonfinancial study support from Genentech and grant funding from Boehringer Ingelheim. N.E.B. reports consulting fees from Deepcell. L.B.W. has received advisory board fees from CSL Behring, Quark, Bayer and Merck, and has research contracts with Genentech and CSL Behring. T.S.B. reports consulting fees from Orinove, GRI Bio, Morphic and Novelstar Pharmaceuticals, research grants and contracts from Boehringer Ingelheim and Celgene, and nonfinancial study support from Genentech. R.W. reports consultant fees from Genentech and Boehringer Ingelheim. The remaining authors declare no competing interests.
